FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

The FLIPI24 model robustly stratifies, at diagnosis, patients with FL at increased risk of lymphoma-related death versus patients with very low lymphoma-related mortality during the first decade after diagnosis. FLIPI24 can be used to enrich future clinical trial designs in newly diagnosed FL.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-12-02
DOI
https://doi.org/10.1200/jco-25-00892
Citations
1
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.47

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

Hervé Tilly, Eliza A. Hawkes, Michael Roost Clausen, Richard Burack et al.
1 citations
Journal of Clinical Oncology
Lymphoma Diagnosis and Treatment
1.47
article

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma

Hervé Tilly, Eliza A. Hawkes, Michael Roost Clausen, Richard Burack, Jonathon Brett Cohen, Vít Procházka, Tomáš Fürst, Maher K. Gandhi, Elliot Cahn, Thomas Matthew Habermann, Laurie H. Sehn, Andrea Janíková, Corinne Haïoun, Guillaume Cartron, Peter de Nully Brown, Tarec Christoffer El‐Galaly, Loretta J. Nastoupil, Jonathan W. Friedberg, Lasse Jakobsen, Peter Martin, Robert Kridel, Diego R. Villa, Izidore S. Lossos, Franck Morschhauser, Emmanuel Bachy, Dai Chihara, Matthew J. Maurer, Ciara L. Freeman, David Belada, Marguerite Fournier, Brad S. Kahl, Chan Yoon Cheah, Andrew John Davies, Björn E. Wahlin, James R. Cerhan, Hervé Ghesquières, John Francis Seymour, Christopher R. Flowers, Brian K. Link, Heidi Móciková, Caroline E. Dietrich, Gilles Salles, Marek Trněný, Karin E. Smedby, Yucai Wang, Carla Casulo, Melissa C. Larson, Pierre Feugier
article en
1 citations

Abstract

The FLIPI24 model robustly stratifies, at diagnosis, patients with FL at increased risk of lymphoma-related death versus patients with very low lymphoma-related mortality during the first decade after diagnosis. FLIPI24 can be used to enrich future clinical trial designs in newly diagnosed FL.

Journal of Clinical OncologyVol. 44(2)
Université Claude Bernard Lyon 1 (FR), University of Iowa (US), Centre National de la Recherche Scientifique (FR), Translational Research Institute (AU), Memorial Sloan Kettering Cancer Center (US), Karolinska University Hospital (SE), The University of Texas MD Anderson Cancer Center (US), University of British Columbia (CA), Emory University (US), The University of Queensland (AU), The University of Western Australia (AU), Washington University in St. Louis (US), Cornell University (US), Charles University (CZ), Masaryk University (CZ), Aalborg University Hospital (DK), Peter MacCallum Cancer Centre (AU), Odense University Hospital (DK), Spinal Cord Injury BC (CA), Sir Charles Gairdner Hospital (AU), Princess Margaret Cancer Centre (CA), Rigshospitalet (DK), Karolinska Institutet (SE), University of Rochester Medical Center (US), Centre Hospitalier Universitaire de Lille (FR), Moffitt Cancer Center (US), Vejle Sygehus (DK), Mater Research (AU), Centre Hospitalier Universitaire de Montpellier (FR), Assistance Publique – Hôpitaux de Paris (FR), Piedmont Cancer Institute (US), Centre Hospitalier Régional et Universitaire de Nancy (FR), The Lymphoma Academic Research Organisation (FR), University Hospital Olomouc (CZ), Délégation Centre-Est (FR), Hôpital Lyon Sud (FR), Mayo Clinic in Arizona (US), Hôpitaux Universitaires Henri-Mondor (FR), University Hospital Hradec Králové (CZ), Mercy Regional Medical Center (US), Mayo Clinic in Florida (US), Lymphoma Study Association (FR), University Hospital Kralovske Vinohrady (CZ), Sylvester Comprehensive Cancer Center (US), Olivia Newton-John Cancer Wellness & Research Centre (AU), University of Southampton (GB), Centre Henri Becquerel (FR), Weill Cornell Medicine (US), Génomique du cancer et du cerveau, University of Rochester (US), Palacký University Olomouc (CZ)
Mater Foundation, Cancerfonden, National Institutes of Health, Medical Research Council, National Cancer Institute
Openalex Percentile: Top 13%
Lymphoma Diagnosis and Treatment
1.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.